These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11216334)

  • 1. Cost-effective treatment of depression with selective serotonin reuptake inhibitors.
    Panzarino PJ; Nash DB
    Am J Manag Care; 2001 Feb; 7(2):173-84. PubMed ID: 11216334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sertraline. A pharmacoeconomic evaluation of its use in depression.
    Davis R; Wilde MI
    Pharmacoeconomics; 1996 Oct; 10(4):409-31. PubMed ID: 10184609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Course and cost of treatment for depression with fluoxetine, paroxetine, and sertraline.
    Russell JM; Berndt ER; Miceli R; Colucci S; Grudzinski AN
    Am J Manag Care; 1999 May; 5(5):597-606. PubMed ID: 10537866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retrospective analysis of the health-care costs of bupropion sustained release in comparison with other antidepressants.
    Poret AW; Neslusan C; Ricci JF; Wang S; Khan ZM; Kwong JW
    Value Health; 2001; 4(5):362-9. PubMed ID: 11705126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The economics of selective serotonin reuptake inhibitors in depression: a critical review.
    Frank L; Revicki DA; Sorensen SV; Shih YC
    CNS Drugs; 2001 Jan; 15(1):59-83. PubMed ID: 11465013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomised controlled trial to compare the cost-effectiveness of tricyclic antidepressants, selective serotonin reuptake inhibitors and lofepramine.
    Peveler R; Kendrick T; Buxton M; Longworth L; Baldwin D; Moore M; Chatwin J; Goddard J; Thornett A; Smith H; Campbell M; Thompson C
    Health Technol Assess; 2005 May; 9(16):1-134, iii. PubMed ID: 15876362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year costs of second-line therapies for depression.
    Sullivan EM; Griffiths RI; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    J Clin Psychiatry; 2000 Apr; 61(4):290-8. PubMed ID: 10830151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Expenditure, Price, and Utilization in the U.S. Medicaid: A Trend Analysis for SSRI and SNRI Antidepressants from 1991 to 2018.
    Alrasheed M; Hincapie AL; Guo JJ
    J Ment Health Policy Econ; 2021 Mar; 24(1):3-11. PubMed ID: 33739932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does the use of SSRIs reduce medical care utilization and expenditures?
    Chung S
    J Ment Health Policy Econ; 2005 Sep; 8(3):119-29. PubMed ID: 16278500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacological treatment of depression with and without headache disorders: an appraisal of cost effectiveness and cost utility of antidepressants.
    Pan YJ; Kuo KH; Wang SJ
    J Affect Disord; 2015 Jan; 170():255-65. PubMed ID: 25261631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The economic impact of introducing serotonin-noradrenaline reuptake inhibitors into the Brazilian national drug formulary: cost-effectiveness and budget-impact analyses.
    Machado M; Iskedjian M; Ruiz IA; Einarson TR
    Pharmacoeconomics; 2007; 25(11):979-90. PubMed ID: 17960955
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tricyclic antidepressant and selective serotonin reuptake inhibitors antidepressant selection and health care costs in the naturalistic setting: a multivariate analysis.
    Hylan TR; Crown WH; Meneades L; Heiligenstein JH; Melfi CA; Croghan TW; Buesching DP
    J Affect Disord; 1998 Jan; 47(1-3):71-9. PubMed ID: 9476746
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical resource use and cost of venlafaxine or tricyclic antidepressant therapy. Following selective serotonin reuptake inhibitor therapy for depression.
    Griffiths RI; Sullivan EM; Frank RG; Strauss MJ; Herbert RJ; Clouse J; Goldman HH
    Pharmacoeconomics; 1999 May; 15(5):495-505. PubMed ID: 10537966
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
    Sheehan DV; Eaddy MT; Shah MB; Mauch RP
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE; Regan TS; Chiao E; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacoeconomic analysis of venlafaxine in the treatment of major depressive disorder.
    Einarson TR; Addis A; Iskedjian M
    Pharmacoeconomics; 1997 Aug; 12(2 Pt 2):286-96. PubMed ID: 10170453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The pharmacoeconomics of venlafaxine in depression.
    Morrow TJ
    Am J Manag Care; 2001 Sep; 7(11 Suppl):S386-92. PubMed ID: 11570029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased use of antidepressants in Wuhan, China: a retrospective study from 2006 to 2012.
    Gao P; Zhang H; Xu H; Zhang C; Liu D
    Medicina (Kaunas); 2013; 49(12):529-34. PubMed ID: 24858993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.